A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer

200718 citationsJournal Article

Authors

Craig Underhill

David Goldstein · Prince of Wales Hospital

Vera Gorbounova · Russian Cancer Research Center NN Blokhin

M. Biakhov · Central Clinical Hospital No 2 named Semashko

I. Bazin · Russian Cancer Research Center NN Blokhin

Д. А. Гранов · Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology

Anwar M. Hossain · Eli Lilly (United States)

Abstract

Neither efficacy nor safety improved on the ALIRI arm compared to the FOLFIRI arm. Progression-free survival on FOLFIRI was significantly longer compared to ALIRI. Potential biomarkers capable of predicting response to either regimen in advanced or metastatic colorectal carcinoma need further characterization.

Topics & Keywords

Colorectal Cancer Treatments and Studies Colorectal and Anal Carcinomas Gastric Cancer Management and Outcomes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Oncology

Volume 73, Issue 1-2, pp. 9-20

DOI: 10.1159/000120626

Field-Weighted Citation Impact: 0.59